BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18039077)

  • 1. Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial.
    Lass-Flörl C
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):929-32. PubMed ID: 18039077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
    Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
    Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
    Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
    Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
    Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data.
    Muñoz P; Guinea J; Narbona MT; Bouza E
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S125-31. PubMed ID: 19013336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
    Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
    Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?
    Mihu CN; Kassis C; Ramos ER; Jiang Y; Hachem RY; Raad II
    Cancer; 2010 Nov; 116(22):5290-6. PubMed ID: 20665889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.
    Nucci M; Biasoli I; Akiti T; Silveira F; Solza C; Barreiros G; Spector N; Derossi A; Pulcheri W
    Clin Infect Dis; 2000 Feb; 30(2):300-5. PubMed ID: 10671332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
    Kirkpatrick WR; Coco BJ; Patterson TF
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
    Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Faucher C; Fürst S; Duran S; Berger P; Vey N; Stoppa AM; Bouabdallah R; Gastaut JA; Viens P; Blaise D; Mohty M
    Bone Marrow Transplant; 2007 Mar; 39(5):301-6. PubMed ID: 17262059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial design for mold-active agents: time to break the mold--aspergillosis in neutropenic adults.
    Anaissie EJ
    Clin Infect Dis; 2007 May; 44(10):1298-306. PubMed ID: 17443466
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
    Ho KM; Duff O; Chambers D; Murray R
    Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
    Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
    Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
    Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
    Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
    Chakraborty KK; Naik SR
    J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
    Caillot D; Thiébaut A; Herbrecht R; de Botton S; Pigneux A; Bernard F; Larché J; Monchecourt F; Alfandari S; Mahi L
    Cancer; 2007 Dec; 110(12):2740-6. PubMed ID: 17941026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.
    Martín MT; Gavaldà J; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Jordano Q; Ruiz I; Rosal M; Almirante B; Pahissa A
    J Antimicrob Chemother; 2003 Dec; 52(6):1032-4. PubMed ID: 14613950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.